Celcuity’s Earnings Call: Big Data, Bigger Ambitions

Celcuity Inc. ((CELC)) has held its Q4 earnings call. Read on for the main highlights of the call.

Celcuity’s latest earnings call struck a notably optimistic tone, as management emphasized powerful Phase III results, a fast-track regulatory path and solid funding that could carry the company into commercialization. While losses and cash burn are rising sharply, executives framed this as a deliberate investment phase ahead of a potential 2026 launch of lead drug gedatolisib.

Priority FDA Review Sets Stage for 2026 Decision

The FDA has accepted Celcuity’s NDA for gedatolisib under the Real-Time Oncology Review program and granted Priority Review, setting a PDUFA date of July 17, 2026. This milestone effectively locks in a clear regulatory timetable and positions the company for a potential first commercial approval and launch in 2026 if the data support approval.

VIKTORIA‑1 Wild-Type Data Signal Practice-Changing Potential

In the PIK3CA wild-type cohort of VIKTORIA‑1, the gedatolisib triplet delivered a median progression-free survival of 9.3 months versus 2.0 months on fulvestrant alone, an improvement of 7.3 months with a hazard ratio of 0.24. Subgroup results were even more striking, with median PFS of 19.3 months in U.S./Canada and 16.6 months across major regions, and a 31‑point higher response rate versus control.

Manageable Safety Profile Supports Use in Broad Population

Management highlighted that the gedatolisib triplet was generally well tolerated, with mostly low-grade side effects and treatment-related discontinuations at only about 2.3%. Stomatitis was effectively managed, resolving in roughly two weeks even at higher grades, and importantly there were no clinically meaningful hypoglycemia issues or glucose-driven dose changes.

Quality-of-Life Data Bolster Clinical Differentiation

Patient-reported outcomes showed that time to definitive deterioration stretched to 23.7 months on the gedatolisib regimen versus just 4.0 months on fulvestrant, corresponding to a hazard ratio of 0.39. Celcuity stressed that patients’ overall well-being remained stable for the first eight treatment cycles, underscoring a favorable balance between efficacy and quality of life.

Peer-Reviewed Publication Elevates Scientific Credibility

The VIKTORIA‑1 wild-type data have been showcased in late-breaking oral sessions at ESMO and the San Antonio Breast Cancer Symposium, putting them in front of the oncology community’s key opinion leaders. Publication in the Journal of Clinical Oncology adds another layer of validation that could help drive clinician awareness ahead of any commercial launch.

Mutant Cohort Readout Is Next Major Catalyst

Celcuity has fully enrolled the PIK3CA‑mutant cohort of VIKTORIA‑1, with top-line results expected in the second quarter of 2026, followed by a detailed presentation at a major medical meeting. Management is deliberately limiting disclosures until then, promising only high-level statistical outcomes in the initial press release, which keeps investors waiting on the magnitude of benefit.

Early Prostate Cancer Data Expand Pipeline Optionality

In metastatic castration-resistant prostate cancer, a Phase Ib study of gedatolisib plus darolutamide in 38 patients produced a 6‑month radiographic PFS rate of 67% and median rPFS of 9.1 months across dose arms. These data compare favorably to historical benchmarks around 40% at six months, and the absence of dose-limiting toxicities or AE-driven discontinuations supports further dose escalation and development.

Commercial Build Targets Multi-Billion-Dollar Market

Celcuity reported that key commercial infrastructure is largely in place, including a sales force and payer engagement efforts to prepare for launch. The company pegs its U.S. addressable population at about 37,000 second-line HR+/HER2‑ patients post-CDK4/6 therapy, implying a total addressable market above $5 billion and a potential peak revenue opportunity approaching $2.5 billion under illustrative duration assumptions.

Cash Reserves Provide Runway Through 2027

The company ended fiscal 2025 with $441.5 million in cash, cash equivalents and short-term investments, and management expects this to fund operations through 2027. That runway should carry Celcuity through the PDUFA decision, VIKTORIA‑1 mutant readout and early commercial ramp, reducing the near-term need for dilutive financing despite elevated spending.

Losses Widen as Investment Cycle Intensifies

GAAP net loss for the fourth quarter rose to $51.0 million, or $0.97 per share, versus $36.7 million, or $0.85 per share, a roughly 39% increase year over year. For full-year 2025, GAAP net loss climbed to $177.0 million, or $3.79 per share, up about 58% from 2024, reflecting higher development and commercialization costs.

Non-GAAP Metrics Tell Similar Story of Expanding Spend

Non-GAAP adjusted net loss in the fourth quarter reached $38.4 million, or $0.73 per share, up nearly 19% from $32.3 million a year earlier. For 2025 as a whole, adjusted net loss rose to $150.8 million, or $3.22 per share, about 48% higher than 2024 as Celcuity ramped investments ahead of potential market entry.

R&D and G&A Surge with Trials and Launch Prep

R&D expenses in the fourth quarter increased to $37.6 million, with full-year R&D reaching $145.0 million, up more than 39% year over year due to expanded clinical work and added commercial-related headcount. General and administrative costs jumped even faster, to $11.6 million in Q4 and $27.2 million for the year, nearly tripling versus 2024 as infrastructure and stock-based compensation rose.

Operating Cash Burn Rises Alongside Execution Risk

Net cash used in operating activities climbed to $36.4 million in the fourth quarter and $153.3 million for the year, representing an approximately 84% year-over-year increase in annual burn. Management framed this as consistent with transitioning into a late-stage, pre-commercial biotech, but it underscores the importance of flawless execution and future revenue ramp to justify the spend.

Limited Visibility and Competitive Landscape Remain Watchpoints

Celcuity is intentionally tight-lipped on the PIK3CA‑mutant cohort and will reveal only limited top-line data initially, leaving uncertainty around the broader label potential. Leaders also acknowledged a competitive PI3K and HR+ breast cancer landscape, where payer decisions, reimbursement dynamics and IV administration logistics could all affect uptake once on the market.

Guidance Highlights Key 2026 Catalysts and Funding Horizon

Management reaffirmed that the gedatolisib NDA is under Priority Review with a July 17, 2026 PDUFA date, while top-line data from the PIK3CA‑mutant VIKTORIA‑1 cohort are expected in the second quarter of 2026 and VIKTORIA‑2’s Phase III design update is slated for the same timeframe. Ongoing prostate studies, robust PFS and quality-of-life metrics in the wild-type cohort, and a cash runway through 2027 frame a catalyst-rich period that could reshape Celcuity’s profile from development-stage biotech to commercial oncology player.

Celcuity’s call painted the picture of a company on the cusp of a major inflection, trading near-term financial losses and higher cash burn for the chance at a transformative breast cancer franchise. For investors comfortable with regulatory and launch execution risk, the combination of strong Phase III data, defined 2026 catalysts and ample cash offers a compelling, if volatile, growth narrative.